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Poster Session I S199performance are more likely to randomize patients into more effica-
cious, less toxic and less futile treatment regimens. Our research fo-
cuses on Phase II clinical trials measuring both efficacy and futility,
where randomization is based on performance between the treat-
ment arms. Retrospective data on 373 autologous transplant patients
undergoing mobilization from the VCU Massey Cancer Center are
used to simulate two prospective clinical trials with adaptive random-
ization. The cohort consists of adult patients diagnosed with either
HD, MM or NHL, and were assigned by their treating physician
into one of four mobilization groups: prelixafor (P, n5 19), chemo-
therapy1GCSF (Chemo, n 5 96), GCSF alone (GCSF, n 5 222)
and prelixafor early intervention (PEI, n 5 36). The first study de-
fines success as attainment of at least 5x106 total CD341 cells/kg
in less than 5 days, with futility defined as failing to collect at least
2x106 total CD341 cells/kg. The second study defines success as at-
tainment of at least 5x106 total CD341 cells/kg, with futility defined
as needing at least 5 days for CD341 collection. Results for the both
studies using the two-outcome adaptive randomization methodol-
ogy are found in the Table, showing the various accruement points
at which the efficacy rate for the Chemo group is higher than that
for the other groups with probability 0.95 for Study 1 and 0.99 for
Study 2. Conclusions are reached before the planned end of both
studies, reducing the number of patients by 99 in Study 1 and 261
in Study 2, since a conventional study requires at least 320 patients.
Differences in outcomes and patient numbers between these two
studies illustrate the importance of stringent success and futility def-
initions. Querying this cohort using other clinically relevant out-
comes, cost or toxicity endpoints may alter both cohort size and
conclusions. As shown through example, Bayesian adaptive random-
ization has the potential to reduce the time needed to reach a study’s
conclusion and ultimately reduce the amount of resources needed to
conduct a trial.
Table 1. Total and group accruement when Chemo efficacy
rate conclusively exceeds other groupsTotal 154 Total 171 Total 221
Study 1 Chemo 95 Chemo 96 Chemo 96P 7 GCSF 53 PEI 23Total 33 Total 38 Total 59
Study 2 Chemo 8 Chemo 12 Chemo 32PEI 7 P 7 GCSF 9124
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Purpose: We conducted an economic evaluation of the cost-utility
of using Plerixafor with G-CSF (G1P) for stem cell mobilization
in patients with diffuse large B-cell non-Hodgkin Lymphoma
(DLBCL) versus using G-CSF (G) alone.
Methods: A decision analytic model was constructed, using data
from various sources, to replicate the process of a patient receiving
high-dose chemotherapy proceeding through stem cell mobilization,
apheresis, and transplant (ASCT). Data from the Washington
University site of the Plerixafor Phase III study were used to model
stem cell mobilization and apheresis (n 5 20). The probability of
mortality post-ASCT and utility values were taken from the litera-
ture. Medicare allowable costs were used. Microsimulation was
used to estimate the incremental cost-utility ratio (ICUR) from a so-
cietal perspective, with the patient’s remaining lifetime as the time
horizon.
Results: 100% (10/10) receiving P1G for stem cell mobilization
proceeded to ASCT, versus only 70% (7/10) of those receiving
G. Patients who did not proceed to transplant were assumed to
not contribute any cost or QALYs to the final model result. The ex-
pected lifetime cost of care for DLBCL for a person receiving P1G
was $25,567 more than one receiving G, and also accumulated 1.74more quality adjusted life years (QALYs) for an ICUR of $14,735/
QALY, because of the greater probability of undergoing transplant.
This is under the willingness to pay of $50,000/QALY accepted in
many industrialized nations. Sensitivity analyses revealed that this
$50,000/QALY standard was met so long as the probability of
transplant was greater than 77% in the G1P arm.
Conclusion:The use of plerixafor plus G-CSF for stem cell mo-
bilization for ASCT in patients with DLBCL will likely meet
most accepted standards of cost-effectiveness. This economic
benefit is largely the result of the effectiveness of the P1G reg-
imen in insuring that patients achieve sufficient cell counts prior
to ASCT.
Table 1. Plerixafor Plus G-CSF Costs and QALY’s
IncrementalStrategyTotal
Cost ($)Incremental
Cost ($)Total
Effectiveness
(QALY’s)*Incremental
Effectiveness
(QALY’s)*Cost-Effectiveness
Ratio (Cost /
QALY’s)*G-CSF Alone 67508 5.06Plerixafor
and G-CSF93076 25567 6.80 1.74 14735*Quality Adjusted LIfe Years125
A PHASE 1 STUDY OF BENDAMUSTINE AND MELPHALAN CONDITIONING
FOR AUTOLOGOUS STEM CELL TRANSPLANT IN MULTIPLE MYELOMA
Mark, T.M., Niesvizky, R., Gergis, U., Pearse, R.N., Mayer, S.,
Feldman, E.J., Shore, T.B. Weill Cornell Medical College, New York, NY
Background: Given data showing efficacy of bendamustine in
treating multiple myeloma (MM), we hypothesized that the addi-
tion of bendamustine to autologous stem cell transplant (ASCT)
conditioning would enhance response without significant toxicity
change. We now report the results of the first 4 cohorts of a phase
1 study of bendamustine 1 melphalan conditioning ASCT in
MM.
Methods: Fifteen patients were enrolled onto a 313 phase 1 study of
bendamustine added to melphalan 200mg/m2 split on subsequent
days. Bendamustine was given at the following dose levels on the in-
dicated days of melphalan: 1) 30 mg/m2 given on day 2; 2) 60 mg/m2
on day 2; 3) 90 mg/m2 on day 2; 4) 60mg/m2 on days 1 and 2. Stem
cell infusion of. 2 million 106 CD341 cells/kg was performed at
24-48 hours after the final dose of melphalan. All received G-CSF
with standard supportive care until engraftment, defined as absolute
neutrophil count . 500/ml and a platelet count . 20,000/ml with-
out transfusion. Bonemarrow biopsy and skeletal imagingwere prior
to and 100 days after ASCT to assess baseline and post-ASCT dis-
ease status. MM assessment was done monthly to assess disease re-
sponse as per accepted criteria.
Results: Fifteen patients completed ASCT over 4 cohorts: 3 in
dose level 1, 6 at dose level 2, and 3 each in dose levels 3 and 4.
Median time(range) to wbc engraftment and platelet engraftment
was 11 (9-13) days and 12 (11-27) days, respectively. No trans-
plant-related deaths occurred. Other than one patient with respira-
tory decompensation in the setting of neutropenic fever cohort 2 (a
dose limiting toxicity-DLT), only Grade 1 ASCT-associated toxic-
ity was seen: stomatitis in 8 (57%), diarrhea in 2 (14%), palpita-
tions / sinus tachycardia in 5 (36%), rash in 1 (7%), steroid-
psychosis in 1 (7%), and mild dyspnea in 1 (7%). Seven patients
(50%) had fever prior to wbc engraftment, with bacteremia in 3
(21%) and fungal infection in 1 (7%). At present, there are 11
evaluable MM responses at . 100 days post-ASCT. Three patients
(27%) died from MM, all beyond 100 days post-ASCT. In the
other 8, Day 100 response was complete remission in 6 (55%),
very good partial remission in 1 (9%), and minimal response in 1
(9%).
Summary: Bendamustine added to ASCT conditioning inMMdose
not exacerbate expected toxicities. TheMTDof bendamustine is still
unknown. The high complete remission rate, the best surrogate for
survival in MM, suggests a highly active regimen that should be ex-
plored.
